Immunological Medicine最新文献_第6页

Possible correlation between serum interleukin-8 levels and the activity of myositis in anti-NXP2 antibody-positive dermatomyositis. 抗 NXP2 抗体阳性皮肌炎患者血清白细胞介素-8 水平与肌炎活动之间可能存在的相关性

IF 4.4

Immunological Medicine Pub Date : 2024-06-01 Epub Date: 2024-01-04 DOI: 10.1080/25785826.2023.2300553

Risa Konishi, Yuki Ichimura, Ryota Tanaka, Hanako Miyahara, Mari Okune, Masahide Miyamoto, Monami Hara, Atsushi Iwabuchi, Hidetoshi Takada, Yasuo Nakagishi, Mao Mizuta, Shuya Kaneko, Masaki Shimizu, Tomohiro Morio, Ichizo Nishino, Toshifumi Nomura, Naoko Okiyama

{"title":"Possible correlation between serum interleukin-8 levels and the activity of myositis in anti-NXP2 antibody-positive dermatomyositis.","authors":"Risa Konishi, Yuki Ichimura, Ryota Tanaka, Hanako Miyahara, Mari Okune, Masahide Miyamoto, Monami Hara, Atsushi Iwabuchi, Hidetoshi Takada, Yasuo Nakagishi, Mao Mizuta, Shuya Kaneko, Masaki Shimizu, Tomohiro Morio, Ichizo Nishino, Toshifumi Nomura, Naoko Okiyama","doi":"10.1080/25785826.2023.2300553","DOIUrl":"10.1080/25785826.2023.2300553","url":null,"abstract":"Anti-nuclear matrix protein 2 (NXP2) antibody-positive dermatomyositis (DM) is characterized by extensive and severe myositis. In this study, we evaluated which cytokines/chemokines involved with the activity of the myositis. We performed quantitative immunoassays using the MILLIPLEX® Multiplex Assays Using Luminex to evaluate serum levels of interferon-γ, interleukin (IL)-1β, IL-6, IL-8, IL-12p40, and tumor necrosis factor-α in samples collected over time from a 9-year-old female with anti-NXP2 antibody-positive DM. In our case, the serum level of IL-8 was elevated when the myositis worsened, and decreased in accordance with the improvement of myositis, suggesting that the serum IL-8 levels were correlated with the myositis activity. Serum levels of IL-8 in samples from five patients with anti-NXP2 antibody-positive DM and five patients with anti-transcriptional intermediary factor 1γ (TIF1γ) antibody-positive DM without both interstitial lung disease (ILD) and malignancy before starting treatments, along with five healthy controls, were also evaluate by an enzyme-linked immunosorbent assay. Serum IL-8 levels were significantly elevated in anti-NXP2 or anti-TIF1γ antibody-positive DM patients with myositis but not ILD, than healthy controls. It was suggested that serum levels of IL-8 correlate with the activity of myositis in DM including anti-NXP2 antibody-positive DM.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"100-105"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139088924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study. 前瞻性队列研究：霉酚酸酯减少神经脊髓炎视网膜频谱障碍类固醇用药的有效性和安全性。

IF 2.7

Immunological Medicine Pub Date : 2024-06-01 Epub Date: 2024-01-18 DOI: 10.1080/25785826.2024.2304364

Ritsu Akatani, Norio Chihara, Shusuke Koto, Sotaro Mori, Takuji Kurimoto, Makoto Nakamura, Hisatsugu Tachibana, Yoshihisa Otsuka, Takehiro Ueda, Takashi Omori, Kenji Sekiguchi, Riki Matsumoto

引用次数: 0

Synovial-tissue resident macrophages play proinflammatory functions in the pathogenesis of RA while maintaining the phenotypes in the steady state. 滑膜组织常住巨噬细胞在 RA 的发病机制中发挥促炎功能，同时在稳定状态下保持表型。

IF 4.4

Immunological Medicine Pub Date : 2024-06-01 Epub Date: 2024-01-03 DOI: 10.1080/25785826.2023.2300853

Kazuhiro Kai, Hisakata Yamada, Ryosuke Tsurui, Koji Sakuraba, Kenjiro Fujimura, Shinya Kawahara, Yukio Akasaki, Hidetoshi Tsushima, Toshifumi Fujiwara, Daisuke Hara, Jun-Ichi Fukushi, Shinichiro Sawa, Yasuharu Nakashima

{"title":"Synovial-tissue resident macrophages play proinflammatory functions in the pathogenesis of RA while maintaining the phenotypes in the steady state.","authors":"Kazuhiro Kai, Hisakata Yamada, Ryosuke Tsurui, Koji Sakuraba, Kenjiro Fujimura, Shinya Kawahara, Yukio Akasaki, Hidetoshi Tsushima, Toshifumi Fujiwara, Daisuke Hara, Jun-Ichi Fukushi, Shinichiro Sawa, Yasuharu Nakashima","doi":"10.1080/25785826.2023.2300853","DOIUrl":"10.1080/25785826.2023.2300853","url":null,"abstract":"Synovial tissue-resident macrophages (STRMs) maintain normal joint homeostasis in a steady state. However, it is unclear whether STRMs still play homeostatic roles or change the functions in the joint of rheumatoid arthritis (RA), where infiltrating peripheral blood monocyte-derived macrophages (PBMoMs) play proinflammatory roles. In the present study, we examined changes in the phenotypes and functions of STRMs in response to RA-related stimuli in vitro. STRMs were prepared from non-inflammatory osteoarthritis (OA) joint synovium, which is histologically indistinguishable from normal joint synovium. PBMoMs were prepared and used for comparison. After stimulation with plate-bound IgG, which mimics anti-citrullinated protein antibody immunocomplex formed in RA joints, or with combinations of RA-related inflammatory mediators, namely tumor necrosis factor-α (TNF-α) and prostaglandin E2 or interferon-γ, PBMoMs downregulated surface markers and genes associated with anti-inflammatory macrophages, and upregulated cytokine and marker genes of proinflammatory macrophages in RA. On the other hand, STRMs hardly changed the expression of surface molecules and marker genes but altered the pattern of cytokine gene expression after stimulation like PBMoMs. Furthermore, in vitro stimulated STRMs promote proinflammatory functions of cocultured synovial fibroblasts. Thus, STRMs might play proinflammatory roles in RA joints, while maintaining their phenotypes in the steady state.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"58-67"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139088925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus. 系统性红斑狼疮患者接种 SARS-CoV-2 mRNA 疫苗后疾病复发的风险。

IF 4.4

Immunological Medicine Pub Date : 2024-06-01 Epub Date: 2024-01-08 DOI: 10.1080/25785826.2023.2300163

Jun Kikuchi, Yasushi Kondo, Shuichiro Kojima, Shiho Kasai, Yuma Sakai, Masaru Takeshita, Kazuoto Hiramoto, Shuntaro Saito, Hiroyuki Fukui, Hironari Hanaoka, Katsuya Suzuki, Yuko Kaneko

{"title":"Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus.","authors":"Jun Kikuchi, Yasushi Kondo, Shuichiro Kojima, Shiho Kasai, Yuma Sakai, Masaru Takeshita, Kazuoto Hiramoto, Shuntaro Saito, Hiroyuki Fukui, Hironari Hanaoka, Katsuya Suzuki, Yuko Kaneko","doi":"10.1080/25785826.2023.2300163","DOIUrl":"10.1080/25785826.2023.2300163","url":null,"abstract":"This study aims to elucidate the effectiveness and safety of SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus (SLE). We enrolled uninfected SLE patients who received two vaccine doses (BNT162b2 or mRNA-1273) and historical unvaccinated patients. Neutralizing antibodies, adverse reactions, and disease flares were evaluated 4 weeks after the second vaccination. Ninety patients were enrolled in each group. Among the vaccinated patients, SLE Disease Activity Index (SLEDAI), and prednisolone doses before vaccination were 2, and 5 mg/d, respectively. After the second vaccination, 19 (21.1%) had no neutralizing antibodies. Adverse reactions occurred in 88.9% within 3 d. Negative antibodies were associated with anemia and mycophenolate mofetil administration. SLEDAI increased modestly but significantly after vaccination, with 13 (14.4%) experiencing flares and 4 (4.4%) severe flares (nephritis in three and vasculitis in one). The flare rate was higher in vaccinated patients than unvaccinated controls. The mean duration between the second vaccination and flares was 35 d, and flares occurred at least 8 days after vaccination. Multivariable analysis showed that high SLEDAI and anti-dsDNA antibodies were associated with flares. The vaccine type, neutralizing antibody titer, and adverse reaction frequency did not affect flares. Therefore, residual disease activity before vaccination increases flare risk.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"76-84"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139378443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prophylactic immunoglobulin therapy for pediatric congenital myotonic dystrophy. 小儿先天性肌营养不良症的预防性免疫球蛋白疗法。

IF 2.7

Immunological Medicine Pub Date : 2024-06-01 Epub Date: 2024-01-25 DOI: 10.1080/25785826.2024.2306672

Yoji Uejima, Satoshi Sato

{"title":"Prophylactic immunoglobulin therapy for pediatric congenital myotonic dystrophy.","authors":"Yoji Uejima, Satoshi Sato","doi":"10.1080/25785826.2024.2306672","DOIUrl":"10.1080/25785826.2024.2306672","url":null,"abstract":"Congenital Myotonic Dystrophy (CMD) is an autosomal dominant hereditary disease caused by mutations in the dystrophia myotonica protein kinase gene. Patients with CMD often exhibit low immunoglobulin (Ig) G levels. While Ig replacement therapy for low IgG levels has been reported in several adult cases, there have been no reports on pediatric patients. This study presents a first pediatric case where Ig replacement therapy effectively eliminated susceptibility to infections. The CMD patient, a 1-year-old Japanese female with a history of premature birth and necrotizing enterocolitis, developed recurrent severe bacterial infections due to hypogammaglobulinemia. Intravenous immunoglobulin (IVIG) (600 mg/kg/month) was administered but failed to maintain sufficient serum trough IgG levels. The dosage was increased to 2 g/kg/month, and later, the treatment shifted to subcutaneous immunoglobulin (SCIG), resulting in a stable serum trough IgG level above 700 mg/dL for one year. The cause of hypogammaglobulinemia in CMD patients remains unclear, but potential mechanisms, including IgG-mediated hypercatabolism by alterations in the neonatal Fc receptor, have been considered. Genetic testing ruled out common variable immunodeficiency, and other potential causes were excluded. The study suggests that higher doses of IVIG or SCIG can effectively prevent severe infections associated with CMD-induced hypogammaglobulinemia in children.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"106-109"},"PeriodicalIF":2.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

C5a stimulation induces caspase-1 activation and mature IL-1β production in human peripheral blood mononuclear cells. C5a 刺激可诱导 Caspase-1 活化和人类外周血单核细胞产生成熟的 IL-1β。

IF 4.4

Immunological Medicine Pub Date : 2024-06-01 Epub Date: 2023-12-15 DOI: 10.1080/25785826.2023.2292665

Yuya Fujita, Haruki Matsumoto, Kenji Inada, Michio Onizawa, Kenji Saito, Yuya Sumichika, Shuhei Yoshida, Jumpei Temmoku, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Takeshi Machida, Kiyoshi Migita

{"title":"C5a stimulation induces caspase-1 activation and mature IL-1β production in human peripheral blood mononuclear cells.","authors":"Yuya Fujita, Haruki Matsumoto, Kenji Inada, Michio Onizawa, Kenji Saito, Yuya Sumichika, Shuhei Yoshida, Jumpei Temmoku, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Takeshi Machida, Kiyoshi Migita","doi":"10.1080/25785826.2023.2292665","DOIUrl":"10.1080/25785826.2023.2292665","url":null,"abstract":"The complement component C5a contributes to the recruitment of immune cells to inflamed tissues and local inflammation. The proinflammatory cytokine interleukin (IL)-1β is also related to inflammatory disorders through inflammasome activation. However, the association between inflammasome activation and C5a is unclear. Human peripheral blood mononuclear cells (PBMCs) were stimulated with C5a and measured for IL-1β secretion by enzyme-linked immunosorbent assay (ELISA). The pro-IL-1β expression in cell lysates was also examined by Western blot analysis. Similarly, magnetic bead-isolated CD14+ monocyte-depleted and lymphocyte-depleted PBMCs were stimulated with C5a, and immunoblot analysis was performed using an anti-cleaved-IL-1β (p17) antibody. FACS was performed to detect caspase-1-activated cells. C5a-stimulated PBMCs produced IL-1β in C5a concentration-dependent manner. The protein levels of pro-IL-1β in the cell lysates were significantly increased. Furthermore, the cleaved-IL-1β (p17) was faintly detected in the same lysates. Active caspase-1 was demonstrated in C5a-simulated CD14+ monocytes by FACS. Cleaved-IL-1β (p17) was demonstrated in the supernatant of C5a-stimulated PBMCs. Lymphocyte-depleted PBMCs stimulated with C5a but monocyte-depleted PBMCs produced cleaved-IL-1β (p17). C5a induced the production of mature IL-1β in PBMCs. The IL-1β production is mediated mainly by caspase-1 activation in CD14+ monocytes. These results suggest that C5a alone potentiates mature IL-1β production mainly in monocytes.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"68-75"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathophysiology and stratification of treatment-resistant rheumatoid arthritis. 抗药性类风湿性关节炎的病理生理学和分层。

IF 4.4

Immunological Medicine Pub Date : 2024-03-01 Epub Date: 2023-07-18 DOI: 10.1080/25785826.2023.2235734

Saeko Yamada, Yasuo Nagafuchi, Keishi Fujio

{"title":"Pathophysiology and stratification of treatment-resistant rheumatoid arthritis.","authors":"Saeko Yamada, Yasuo Nagafuchi, Keishi Fujio","doi":"10.1080/25785826.2023.2235734","DOIUrl":"10.1080/25785826.2023.2235734","url":null,"abstract":"Early diagnosis and timely therapeutic intervention are clinical challenges of rheumatoid arthritis (RA), especially for treatment-resistant or difficult-to-treat patients. Little is known about the immunological mechanisms involved in refractory RA. In this review, we summarize previous research findings on the immunological mechanisms of treatment-resistant RA. Genetic prediction of treatment-resistant RA is challenging. Patients with and without anti-cyclic citrullinated peptide autoantibodies are considered part of distinct subgroups, especially regarding long-term clinical prognosis and treatment responses. B cells, T cells and other immune cells and fibroblasts are of pathophysiological importance and are associated with treatment responses. Finally, we propose a new hypothesis that stratifies patients with RA into two subgroups with distinct immunological pathologies based on our recent immunomics analysis of RA. One RA subgroup with a favorable prognosis is characterized by increased interferon signaling. Another subgroup with a worse prognosis is characterized by enhanced acquired immune responses. Increases in dendritic cell precursors and diversified autoreactive anti-modified protein antibodies may have pathophysiological roles, especially in the latter subgroup. These findings that improve treatment response predictions might contribute to future precision medicine for RA.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"12-23"},"PeriodicalIF":4.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7/8 antagonist through academia-industry-government collaboration. 系统性红斑狼疮的一个新的治疗靶点：通过学术界-行业-政府合作开发toll样受体7/8拮抗剂的当前前景。

IF 4.4

Immunological Medicine Pub Date : 2024-03-01 Epub Date: 2023-09-29 DOI: 10.1080/25785826.2023.2264023

Yoshiya Tanaka, Fumitoshi Tago, Naoto Yamakawa, Mari Aoki, Takuya Yagi, Shizuo Akira

{"title":"A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7/8 antagonist through academia-industry-government collaboration.","authors":"Yoshiya Tanaka, Fumitoshi Tago, Naoto Yamakawa, Mari Aoki, Takuya Yagi, Shizuo Akira","doi":"10.1080/25785826.2023.2264023","DOIUrl":"10.1080/25785826.2023.2264023","url":null,"abstract":"Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by inflammation in multiple organs. A few treatments for SLE currently exist, including antimalarials, glucocorticoids, immunosuppressants, and two recently approved antibody agents; however, an unmet medical need remains for SLE. In addition, developing new drugs targeting SLE is a challenge since no specific biomarkers exist for the prediction of disease progression or drug response. A new drug candidate, E6742, is a specific antagonist of the toll-like receptors 7/8. To address the challenges for drug development in SLE, the process of developing E6742 utilizes a unique system of the Japan Agency for Medical Research and Development (AMED), the Cyclic Innovation for Clinical Empowerment (CiCLE) program. In the CiCLE program, a Phase 1 study in healthy adults was completed (NCT04683185) and a Phase 1/2 study in patients with SLE is on-going (NCT05278663). One of the potential benefits of this program is to conduct academia-led clinical research to identify specific biomarkers for E6742 in parallel with clinical studies (UMIN000042037). The aim of this review is to present current progress within the strategic collaboration of the AMED CiCLE program that optimize clinical development for patients with SLE.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"24-29"},"PeriodicalIF":4.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41146837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison and effect of plain and calcium fortified yogurt on glycemic responses, anthropometrics and metabolic biomarkers. 比较普通酸奶和强化钙酸奶对血糖反应、人体测量学和代谢生物标志物的影响。

IF 4.4

Immunological Medicine Pub Date : 2024-03-01 Epub Date: 2023-06-30 DOI: 10.1080/25785826.2023.2228074

Asma Draz, Hafiza Madiha Jaffar, Bahisht Rizwan, Sadia Sukhera, Syeda Aiman Batool, Sana Noreen, Nazia Koser, Zeenat Islam

{"title":"Comparison and effect of plain and calcium fortified yogurt on glycemic responses, anthropometrics and metabolic biomarkers.","authors":"Asma Draz, Hafiza Madiha Jaffar, Bahisht Rizwan, Sadia Sukhera, Syeda Aiman Batool, Sana Noreen, Nazia Koser, Zeenat Islam","doi":"10.1080/25785826.2023.2228074","DOIUrl":"10.1080/25785826.2023.2228074","url":null,"abstract":"Metabolic syndromes including obesity and diabetes are the most common health issues due to insulin resistance, disturbance in glucose homeostasis, lack of exercise, and improper diet. The current study was planned to evaluate the potential effects of regular diet with fortified yogurt on blood glycemia and anthropometric responses. Plain yogurt was procured from the local market, and then it was fortified with calcium. Furthermore, the subsequent effect of fortified yogurt on blood glucose, insulin, and anthropometric measurements was assessed at different time intervals. A total of 40 healthy females and males aged about 20 years with a normal BMI range (20-24.9 kg/m2) were recruited within the Government College University Faisalabad. Participants filled out the habits Performa, stress factors questionnaire, and activity questionnaire. Blood glucose (BG) and visual analogous scale (VAS) performs were also taken in the fasting stage and then assigned treatment was given. After 15, 30, 45, 60, 90, and 120 min intervals VAS and BG estimation was carried out. The results shows that fortified yogurt contained a higher amount of calcium. Likewise, a similar trend was observed for the desire to eat, a feeling of fullness, palatability, physical comfort, and overall acceptability. The results obtained from various analyses were statistically evaluated.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"30-36"},"PeriodicalIF":4.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9696903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osteoclast differentiation in rheumatoid arthritis. 类风湿性关节炎中的破骨细胞分化。

IF 4.4

Immunological Medicine Pub Date : 2024-03-01 Epub Date: 2023-06-13 DOI: 10.1080/25785826.2023.2220931

Kazuhiro Yokota

{"title":"Osteoclast differentiation in rheumatoid arthritis.","authors":"Kazuhiro Yokota","doi":"10.1080/25785826.2023.2220931","DOIUrl":"10.1080/25785826.2023.2220931","url":null,"abstract":"Osteoclasts, derived from the monocyte/macrophage line of bone marrow hematopoietic stem cell progenitors, are the sole bone-resorbing cells of the body. Conventional osteoclast differentiation requires macrophage colony-stimulating factor and receptor activator of nuclear factor kappa-B ligand (RANKL) signaling. Rheumatoid arthritis (RA) is the most prevalent systemic autoimmune disease and inflammatory arthritis characterized by bone destruction. Increased levels of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6), in the serum and joints, cause excessive bone destruction. We have recently reported that stimulation of human peripheral blood monocytes with TNF-α and IL-6 induces the differentiation of osteoclasts with bone resorption activity. This review presents the functional differences between representative osteoclasts, conventional RANKL-induced osteoclasts, and recently identified proinflammatory cytokine (TNF-α and IL-6)-induced osteoclasts in RA patients. We believe novel pathological osteoclasts associated with RA will be identified, and new therapeutic strategies will be developed to target these osteoclasts and prevent the progression of bone destruction.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"6-11"},"PeriodicalIF":4.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9977433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0